"I think a lot of industries are going to be coming back," Trump said. "We have to get our drug industry coming back. Our drug industry has been disastrous. They're leaving left and right. They supply our drugs, but they don't make them here."

The criticism related to the foreign production and supply chain operations of some of the largest companies in the world. In response, to his criticism, NASDAQ Biotechnology Index is down 3 percent.

Interestingly, the president-elect appears to be identifying poor procurement techniques as the chief contributory factor for creating a 'disastrous' drug sector.

“And the other thing we have to do is create new bidding procedures for the drug industry because they're getting away with murder.”

Although it is not clear, the government seems to be the primary target of these remarks. Those in the public sector are commonly fingered for dysfunctional purchasing processes.

Read Full Article